Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Withdrawn 1Terminated 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Multiple Myeloma 2Unspecified Adult Solid Tumor, Protocol Specific 1Resectable Pancreatic Cancer 1Resectable Esophageal Cancer 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pleural Mesothelial Neoplasm 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Leukemia, Prolymphocytic 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Colorectal Neoplasms 1Breast Neoplasms 1Advanced Malignant Solid Tumor 1

Interventions

Dexamethasone 129Lenalidomide 70Cyclophosphamide 70Bortezomib 69Calcium Dobesilate 50fludarabine 44pomalidomide 40daratumumab 37carfilzomib 33fludarabine phosphate 31Melphalan 25dexamethasone acetate 20dexamethasone 21-phosphate 20auricularum 18Filgrastim 18Whole-Body Irradiation 14Biopsy 13isatuximab 12Vorinostat 12Tacrolimus 12Peripheral Blood Stem Cell Transplantation 12Magnetic Resonance Spectroscopy 12Granulocyte Colony-Stimulating Factor 12Specimen Handling 11Sirolimus 11ixazomib 10belantamab mafodotin 10Panobinostat 10Mycophenolic Acid 10Cyclosporine 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Multiple Myeloma × Adjuvants, Immunologic × Clear all
NCT02400242 2024-07-09

Study of ACY-241 Alone and in Combination With Pomalidomide and Dexamethasone in Multiple Myeloma

Celgene

Phase 1 Terminated
85 enrolled
Plasma cell

Multiple Myeloma

NCT05950113 2024-05-01

CART-BCMA/CS1 in Treating Patients With Relapsed or Refractory Multiple Myeloma

Jonsson Comprehensive Cancer Center

Phase 1 Withdrawn
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡